Targeting sphingosine kinase 1 to sensitise acute myeloid leukaemia to BH3 mimetic therapy

靶向鞘氨醇激酶 1 使急性髓系白血病对 BH3 模拟疗法敏感

• 批准号: nhmrc : GNT1145139
• 负责人: Dr Jason Powell
• 金额: $ 67万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-sphingosine-kinase-mimetic-therapy/1348664
• 关键词: Targeting; sphingosine; kinase; sensitise; acute

Acute Myeloid Leukaemia (AML) patients are currently treated with chemotherapeutics and despite their success at achieving disease remission these responses are often short lived, resulting in relapse and death. We have identified sphingosine kinase 1 as a new drug target in AML. This proposal aims to examine the role of targeting sphingosine kinase 1 in combination with new targeted therapies in patient samples and preclinical mouse models of AML.

急性髓系白血病(AML)患者目前正在接受化疗，尽管他们在实现疾病缓解方面取得了成功，但这些反应往往是短暂的，导致复发和死亡。我们已经确定鞘氨醇激酶1是AML的一个新的药物靶点。这项建议旨在研究靶向鞘氨酸激酶1与新的靶向治疗相结合在急性髓细胞白血病患者样本和临床前小鼠模型中的作用。